Quest Diagnostics Incorporated (NYSE:DGX) SVP Sells $246,400.00 in Stock

Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the transaction, the senior vice president now directly owns 13,435 shares of the company’s stock, valued at $1,880,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Quest Diagnostics Price Performance

DGX stock opened at $137.38 on Friday. The company has a market cap of $15.26 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $130.33 and a two-hundred day moving average price of $131.71. Quest Diagnostics Incorporated has a 12-month low of $119.59 and a 12-month high of $145.58.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The company’s revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.04 EPS. As a group, research analysts predict that Quest Diagnostics Incorporated will post 8.78 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Jefferies Financial Group upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $140.00 to $155.00 in a research report on Wednesday, February 7th. Leerink Partnrs reissued a “market perform” rating on shares of Quest Diagnostics in a research note on Monday, February 26th. UBS Group lifted their target price on shares of Quest Diagnostics from $139.00 to $146.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. TheStreet lowered Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. Finally, StockNews.com downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Friday. Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $146.17.

Institutional Investors Weigh In On Quest Diagnostics

Several large investors have recently made changes to their positions in the business. American Century Companies Inc. boosted its position in Quest Diagnostics by 12.3% during the 3rd quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company’s stock worth $433,153,000 after purchasing an additional 388,162 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Quest Diagnostics by 1.8% during the fourth quarter. Victory Capital Management Inc. now owns 3,476,628 shares of the medical research company’s stock worth $479,357,000 after purchasing an additional 62,114 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Quest Diagnostics by 0.7% in the fourth quarter. Wellington Management Group LLP now owns 2,632,326 shares of the medical research company’s stock worth $362,945,000 after buying an additional 18,533 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Quest Diagnostics by 36.8% in the third quarter. JPMorgan Chase & Co. now owns 2,001,347 shares of the medical research company’s stock valued at $243,884,000 after buying an additional 538,377 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Quest Diagnostics by 5.4% during the 3rd quarter. Invesco Ltd. now owns 1,798,803 shares of the medical research company’s stock valued at $219,202,000 after buying an additional 92,542 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.